Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXT007 versus Factor VIII prophylaxis in hemophilia A without inhibitors
jRCT2051250253Phase 3Recruiting
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- May 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of zemocimig in hemophilia A (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Annualized Bleed Rate (ABR) for treated bleeds over the main 6-month study treatment period. Started May 2026; status: recruiting.
02
Drugs
zemocimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on jRCT2051250253.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250253.